newsfilter

$DYAX News

Last published 10y ago

  • 10y agoDYAXDyax Corp. Sets January 21, 2016 As Date of Special Stockholder Meeting To Vote On Its Proposed Acquisition By Shire plcBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX) (“Dyax”) today announced it has set a date for a special meeting of its stockholders to consider and vote on the previously announced proposed acquisition of Dyax by Shire plc and certain other related matters. The special meeting will be held on January 21, 2016, at 1:00 p.m. Eastern Time, at the offices of Dyax, 55 Network Drive, Burli ...
  • 10y agoDYAXDyax Corp. Presents DX-4012 Data at the 2015 American Society of Hematology Annual MeetingBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) today announced a poster presentation describing preclinical data for DX-4012, the Company’s fully human monoclonal antibody to activated Factor XII (Factor XIIa), was presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 5-8, 2015 in Orlando, Florida.
  • 10y agoDYAXDyax Corp. Announces Early Termination of Hart-Scott-Rodino Waiting PeriodBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) (“Dyax”) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), applicable to its proposed acquisition by Shire Pharmaceuticals International (“SPI”), an indirect wholly-owned subsidiary of Shire plc (“Shire”), was terminated by the United States Federal Trade ...
  • 10y agoDYAXDyax Corp. Recognized as a “Top Place to Work” by The Boston Globe for Second Year in a RowBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX), a biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs, today announced that it has been named one of the Top Places to Work in Massachusetts by The Boston Globe for the second year in a row.
  • 11y agoDYAXDyax Corp. Presents Phase 1b DX-2930 Data at the American College of Allergy, Asthma, and Immunology Annual MeetingBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX) today announced that two oral presentations describing clinical data from its DX-2930 Phase 1b study were presented at the American College of Allergy, Asthma, and Immunology (ACAAI) Annual Meeting taking place in San Antonio, Texas. DX-2930 is an investigational fully human monoclonal antibody inhibitor of plasma kallikrein (pKal) being ...
  • 11y agoDYAXSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Dyax Corp. (DYAX) Over the Proposed Sale of the Company to Shire plc.Business WireNEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Dyax Corp. (“Dyax” or the “Company”) (NasdaqGM:DYAX) for potential breaches of fiduciary duties in connection with the sale of the Company to Shire plc. for approximately $5.4 billion.
  • 11y agoDYAXSHPGDyax Corp. Announces Cancellation of Research and Development DayBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX) announced today the cancellation of its previously scheduled Research and Development (R&D) Day, which was set to take place on Monday, November 2, 2015, in New York City.
  • 11y agoDYAXDyax Corp. Announces Third Quarter 2015 Financial ResultsBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) today announced financial results for the third quarter ended September 30, 2015. Dyax will host a webcast to review these results in conjunction with the Company’s Research and Development Day on Monday, November 2, 2015 at 8:00 a.m. (ET).
  • 11y agoDYAXDyax Corp. to Review Third Quarter 2015 Financial Results at Research and Development DayBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) will release third quarter financial results on Wednesday, October 28, 2015 after market close. In lieu of the previously announced third quarter 2015 financial results conference call and webcast, the Dyax management team will review the Company’s third quarter 2015 financial results in conjunction with the Research and Development Day ...
  • 11y agoDYAXDyax Corp. to Webcast 2015 Research and Development DayBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) will host a Research and Development (R&D) Day for institutional investors and research analysts on Monday, November 2, 2015 from 8:00 a.m. to 1:30 pm ET in New York City.
  • 11y agoDYAXDyax Corp. to Host Third Quarter 2015 Financial Results Call and WebcastBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX) will host a webcast and conference call, including an open question and answer session, Wednesday, October 28, 2015. During the call, management will discuss the Company’s financial results for the third quarter 2015 as well as progress regarding its key value drivers – DX-2930, the KALBITOR® (ecallantide) business and the Licensing and ...
  • 11y agoDYAXDyax Corp. Receives Positive Opinion for Orphan Medicinal Product Designation in the European Union for DX-2930 for the Treatment of Hereditary AngioedemaBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX) today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending DX-2930 for designation as an orphan medicinal product for the treatment of hereditary angioedema (HAE). Dyax is developing DX-2930, an investigational fully human monoclonal antibody inhibit ...
  • 11y agoDYAXDyax Corp. to Participate in the Leerink Partners 4th Annual Rare Disease RoundtableBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX) announced today that executive management will participate in the Leerink Partners 4th Annual Rare Disease Roundtable being held September 30, 2015 at Le Parker Meridien Hotel in New York City. The Company is scheduled to present on Wednesday, September 30 at 3:10pm (ET).
  • 11y agoDYAXDyax Corp. to Participate in the Morgan Stanley Global Healthcare ConferenceBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in the Morgan Stanley Global Healthcare Conference being held September 16-18, 2015 at the Grand Hyatt in New York City. The Company is scheduled to present on Friday, September 18 at 11:05am (ET).
  • 11y agoDYAXDyax Corp. Provides Update on DX-2930 Clinical and Commercial Supply InitiativesBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX) today provided an update regarding its ongoing manufacturing initiatives for DX-2930. Discovered by Dyax, DX-2930 is an investigational fully human monoclonal antibody inhibitor of plasma kallikrein being developed for the prevention of hereditary angioedema (HAE) attacks.
  • 11y agoDYAXDyax Corp. to Participate in the 2015 Wedbush PacGrow Healthcare ConferenceBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in the 2015 Wedbush PacGrow Global Healthcare Conference being held August 12-13, 2015 at Le Parker Meridien in New York City. The Company is scheduled to present on Wednesday, August 12 at 9:10am (ET).
  • 11y agoDYAXDyax Corp. Announces Second Quarter 2015 Financial ResultsBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) today announced financial results for the second quarter ended June 30, 2015. Dyax will host a webcast and conference call at 5:00 p.m. (ET) today to review financial results and provide updates on DX-2930, KALBITOR® (ecallantide) and the Licensing and Funded Research Portfolio (LFRP). The Company will also provide an introductory overv ...
  • 11y agoDYAXDyax Corp. to Host Second Quarter 2015 Earnings Call and WebcastBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX) will host a webcast and conference call, including an open question and answer session, Wednesday, July 29, 2015. During the call, management will discuss the Company’s financial results for the second quarter 2015 as well as progress regarding its key value drivers – DX-2930, the KALBITOR® (ecallantide) business and the Licensing and Fu ...
  • 11y agoDYAXDyax Corp. Receives FDA Breakthrough Therapy Designation for DX-2930 for Prevention of Attacks of Hereditary AngioedemaBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for the investigation of DX-2930 for hereditary angioedema (HAE). Dyax is developing DX-2930, an investigational fully human monoclonal antibody inhibitor of plasma kallikrein (pKal), as a subcutaneous injection for prevention of HAE ...
  • 11y agoDYAXDyax Corp. Presents Phase 1b DX-2930 Data at the 2015 European Academy of Allergy and Clinical Immunology Annual CongressBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX) today announced that clinical data from its DX-2930 Phase 1b study was selected as a late-breaking abstract and presented on June 7, 2015 at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress in Barcelona, Spain. Discovered by Dyax, DX-2930 is an investigational fully human monoclonal antibody inhibitor of pl ...
  • 11y agoDYAXDyax Corp. to Participate in the Jefferies 2015 Global Healthcare ConferenceBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in the Jefferies 2015 Global Healthcare Conference being held June 1-4, 2015 at the Grand Hyatt in New York City. The Company is scheduled to present on Monday, June 1 at 3:00pm (ET) and will provide an update on DX-2930, KALBITOR® (ecallantide) and the Licensing and Funded Rese ...
  • 11y agoDYAXDyax and the U.S. Hereditary Angioedema Association (HAEA) Launch the HAE Hope® Essay Contest on the Fourth Annual Hereditary Angioedema DayBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--To mark the fourth annual Hereditary Angioedema (HAE) Day, Dyax Corp. and the HAEA today announced the launch of the HAE Hope Essay Contest. By drawing from the inspiring stories of individuals with HAE nationwide, the program seeks to underscore the value of hope for those living with this potentially life-threatening condition. HAE is characterized by spontane ...
  • 11y agoDYAXDyax Corp. Appoints Dr. Abbie Celniker to Board of DirectorsBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX), a biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs, today announced the appointment of Abbie Celniker, Ph.D., to its Board of Directors.
  • 11y agoDYAXDyax Corp. to Participate in Upcoming Investor ConferencesBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in the following upcoming investor conferences:
  • 11y agoDYAXDyax Corp. Announces First Quarter 2015 Financial ResultsBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) today announced financial results for the first quarter ended March 31, 2015. Dyax will host a webcast and conference call at 5:00 p.m. (ET) today to review financial results and provide updates regarding its key value drivers – including DX-2930, KALBITOR® (ecallantide), and the Licensing and Funded Research Portfolio (LFRP).
  • 11y agoDYAXDyax Corp. to Host First Quarter 2015 Earnings Call and WebcastBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX) will host a webcast and conference call, including an open question and answer session, Wednesday, April 29, 2015. During the call, management will discuss the Company’s financial results for the first quarter 2015 as well as progress regarding its key value drivers – DX-2930, the KALBITOR® (ecallantide) business and the Licensing and Fu ...
  • 11y agoDYAXDyax Closes $230 Million Public Offering of Common StockBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) today announced the closing of an underwritten registered public offering of 8,510,000 shares of its common stock at a price to the public of $27.00 per share. The shares of common stock issued in the offering included 1,110,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase addit ...
  • 11y agoDYAXDyax Corp. to Participate in the 14th Annual Needham Healthcare ConferenceBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX) announced today that executive management will participate in the 14th Annual Needham Healthcare Conference being held April 14-15, 2015 at the Westin Grand Central Hotel in New York City. The Company is scheduled to present on Tuesday, April 14 at 11:20am (ET) and will provide a corporate update on DX-2930, the KALBITOR® (ecallantide) b ...
  • 11y agoDYAXDyax Announces Pricing of $200 Million Public Offering of Common StockBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) today announced the pricing of an underwritten public offering of 7,400,000 shares of its common stock, offered at a price to the public of $27.00 per share. The gross proceeds to Dyax from this offering are expected to be approximately $200 million, before deducting the underwriting discounts and commissions and other estimated offerin ...
  • 11y agoDYAXDyax Announces Proposed Public Offering of 7,000,000 Shares of Common StockBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) today announced that it is offering, subject to market and other conditions, to sell 7,000,000 shares of its common stock in a proposed underwritten public offering. Dyax intends to grant the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of its common stock. All shares to be sold in the offering are being ...
  • 11y agoDYAXDyax Announces Positive Results from Phase 1b Clinical Trial of DX-2930Business WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX) today announced positive safety, pharmacokinetic, biomarker, and efficacy results from the Phase 1b clinical study of their investigational product, DX-2930. Discovered by Dyax, DX-2930 is a fully human monoclonal antibody inhibitor of plasma kallikrein being developed for the prevention of hereditary angioedema (HAE) attacks.
  • 11y agoDYAXDyax Corp. Announces Fourth Quarter and Full Year 2014 Financial ResultsBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) today announced financial results for the fourth quarter and year ended December 31, 2014. Dyax will host a webcast and conference call at 8:30 a.m. (ET) today to review financial results and provide updates regarding its key value drivers – including the KALBITOR® (ecallantide) business, DX-2930 and the Licensing and Funded Research Po ...
  • 11y agoDYAXDyax Corp. to Participate in Upcoming Investor ConferencesBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in the following upcoming investor conferences:
  • 11y agoDYAXDyax Corp. to Host Fourth Quarter and Year End 2014 Earnings Call and WebcastBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) will host a webcast and conference call, including an open question and answer session, Tuesday, February 24, 2015. During the call, management will discuss the Company’s financial results for the fourth quarter and full year 2014 as well as progress regarding its key value drivers - the KALBITOR® (ecallantide) business, DX-2930 and the ...
  • 11y agoDYAXDyax Corp. to Participate in the Leerink Partners 2015 Global Healthcare ConferenceBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in the Leerink Partners 2015 Global Healthcare Conference being held February 11-12, 2015 at the Waldorf Astoria in New York City. The Company is scheduled to present on Wednesday, February 11 at 11:05am (ET) and will provide a corporate update on the KALBITOR® (ecallantide) bus ...
  • 11y agoDYAXDyax Corp. to Participate in the 25th Annual Oppenheimer Healthcare ConferenceBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in the 25th Annual Oppenheimer Healthcare Conference being held December 10-11, 2014 at the Crowne Plaza Hotel in New York City. The Company is scheduled to present on Wednesday, December 10 at 10:20am (ET) and will provide a corporate update on the KALBITOR® (ecallantide) busin ...
  • 11y agoDYAXDyax Corp. Recognized as a “Top Place to Work” by The Boston GlobeBusiness WireBURLINGTON, Mass--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) a biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs, today announced that it has been named one of the Top Places to Work in Massachusetts by The Boston Globe.
  • 12y agoDYAXDyax Corp. Announces Expansion of Phase 1b Clinical Trial for DX-2930Business WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) today announced the expansion of its ongoing Phase 1b clinical trial evaluating DX-2930 to include additional patients and dosing cohorts. Dyax is developing DX-2930, an investigational fully human monoclonal antibody inhibitor of plasma kallikrein, as a subcutaneous injection for prevention of hereditary angioedema (HAE) attacks.
  • 12y agoDYAXDyax Corp. Announces Third Quarter 2014 Financial ResultsBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) today announced financial results for the third quarter ended September 30, 2014. Dyax will host a webcast and conference call at 5:00 p.m. (ET) today to review financial results and provide updates regarding its key value drivers –including the KALBITOR® (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio (L ...
  • 12y agoDYAXDyax Corp. to Host Third Quarter 2014 Earnings Call and WebcastBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX) will host a webcast and conference call, including an open question and answer session, Tuesday, October 28, 2014. During the call, management will discuss the Company’s financial results for the third quarter 2014 as well as progress regarding its key value drivers - the KALBITOR® (ecallantide) business, DX-2930 and the Licensing and Fu ...
  • 12y agoDYAXDyax Corp. to Participate in the Leerink Partners Rare Disease RoundtableBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in the Leerink Partners Rare Disease Roundtable being held October 1, 2014 at the Le Parker Meridien Hotel in New York City and is scheduled to present at 11:30am (ET) that day. The Company will provide a corporate update on the Company’s key value drivers – the KALBITOR® (ecall ...
  • 12y agoDYAXDyax Corp. Highlights Recent Progress in Licensing and Funded Research PortfolioBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX) today highlighted recent progress and upcoming milestones in its Licensing and Funded Research Portfolio (LFRP), including, most recently, licensee Eli Lilly and Company’s announcement of the fourth positive Phase 3 study outcome for CYRAMZA™ (ramucirumab). Product candidates in Dyax’s LFRP are eligible for royalties on the first ten yea ...
  • 12y agoDYAXDyax Corp. Announces Issuance of Two Key U.S. Patents for DX-2930Business WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) today announced that the U.S. Patent and Trademark Office (USPTO) has issued two new patents related to DX-2930, an investigational fully human monoclonal antibody inhibitor of active plasma kallikrein. One patent, assigned U.S. Patent No. 8,816,055, contains claims covering the specific sequence of DX-2930, and the other, assigned U.S. ...
  • 12y agoDYAXDyax Corp. Announces Second Quarter 2014 Financial ResultsBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) today announced financial results for the second quarter ended June 30, 2014. Dyax will host a webcast and conference call at 5:00 p.m. (ET) today to review financial results and provide updates regarding its key value drivers – the hereditary angioedema (HAE) business, including KALBITOR® (ecallantide), DX-2930, and the Licensing and F ...
  • 12y agoDYAXDyax Corp. Announces Publication of Scientific Data for DX-2930 in Peer-Reviewed JournalsBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) today announced the online publication of scientific data for DX-2930, an investigational fully human monoclonal antibody inhibitor of plasma kallikrein (pKal), in two peer-reviewed journals. Dyax, a biopharmaceutical company focused on hereditary angioedema (HAE) and other plasma-kallikrein-mediated disorders, is developing DX-2930 as ...
  • 12y agoDYAXDyax Corp. to Host Second Quarter 2014 Earnings Call and WebcastBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) will host a webcast and conference call, including an open question and answer session, Tuesday, July 29, 2014. During the call, management will discuss the Company’s financial results for the second quarter 2014 as well as progress regarding its key value drivers - the KALBITOR® (ecallantide) business, DX-2930 and the Licensing and Fun ...
  • 12y agoDYAXDyax Corp. to Participate in the 2014 Wells Fargo Healthcare ConferenceBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in the Wells Fargo Healthcare Conference being held June 17-18, 2014 at the InterContinental Hotel in Boston, MA. The Company will present on Tuesday, June 17 at 10:35 AM (ET) and will provide a corporate update on the Company’s key value drivers – the KALBITOR® (ecallantide) bu ...
  • 12y agoDYAXDyax Corp. to Participate in the Jefferies Global Healthcare ConferenceBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in the Jefferies Global Healthcare Conference being held June 2-5, 2014 in New York City. Gustav Christensen, President and Chief Executive Officer of Dyax, will present on Monday, June 2 at 10:30 AM (ET). Mr. Christensen will provide a corporate update on the Company’s key valu ...
  • 12y agoDYAXDyax Corp. Announces Dosing of First Subject in Phase 1b Trial of DX-2930 in Patients with Hereditary AngioedemaBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) today announced dosing of the first subject in its Phase 1b clinical study of DX-2930 in hereditary angioedema (HAE) patients. The study is designed to evaluate the safety, tolerability, and pharmacokinetics of multiple subcutaneous administrations of DX-2930, an investigational fully human monoclonal antibody inhibitor of plasma kallik ...
  • 12y agoDYAXDyax Corp. to Participate in the Deutsche Bank 39th Annual Health Care ConferenceBusiness WireBURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in the Deutsche Bank 39th Annual Health Care Conference being held May 7-8, 2014 at the InterContinental Hotel in Boston, MA. George Migausky, Chief Financial Officer of Dyax, will present on Wednesday, May 7 at 11:20 AM (ET). Mr. Migausky will provide a corporate update on the ...